ライフサイエンスコーパス: corticotropin-releasing factor

1 excitability induced by the stress hormone, corticotropin releasing factor.

2 ORs that colocalize with the stress hormone, corticotropin releasing factor.

3 e diuretic hormone 44 (DH44), an ortholog of corticotropin-releasing factor.

4 he transmembrane domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to dev

5 An orally active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 sh

6 ective, and orally active antagonists of the corticotropin-releasing factor 1 (CRF 1) receptor.

7 ist (eticlopride), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (anta

8 urthermore, pharmacologic inhibition (with a corticotropin-releasing factor 1 receptor antagonist) of

9 s was identified as potent and orally active corticotropin-releasing factor-1 (CRF(1)) receptor antag

10 ctive withdrawal-like state characterized by corticotropin-releasing factor-1 (CRF(1)) receptor antag

11 Evidence suggests that corticotropin-releasing factor-1 (CRF(1)) receptor antag

12 ation of 8, an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF(1)) receptor antag

13 rmittent access to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagon

14 Corticotropin-releasing factor, a stress-related neurope

15 amine and opioid peptide function, increased corticotropin-releasing factor activity).

16 hine exposure sensitizes the LC-NE system to corticotropin releasing factor and stress.

17 t of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neu

18 alcohol drinking by increased expression of corticotropin-releasing factor and its feedback regulati

19 ween the N/OFQ and Hcrt systems in which the corticotropin-releasing factor and N/OFQ systems coordin

20 that promote stress and resilience, such as corticotropin-releasing factor and nociceptin, has been

21 This parallels a similar effect of corticotropin-releasing factor and suggests a form of ne

22 nsatory mechanism in the brain to counteract corticotropin-releasing factor and/or stress.

23 fering the neural stress response induced by corticotropin releasing factor, and promoting stress res

24 including hypocretin/orexin, norepinephrine, corticotropin-releasing factor, and cytokines.

25 by a variety of central (eg, neuropeptide Y, corticotropin-releasing factor, and neuromedin U) and pe

26 cuses on the HPA axis-based interventions of corticotropin-releasing factor antagonists and the gluco

27 cial behavior (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol

28 Corticotropin releasing factor binding protein (CRF-BP)

29 Corticotropin releasing factor-binding protein (CRF-BP)

30 Corticotropin-releasing factor binds with high affinity

31 88-induced c-Fos activation were observed in corticotropin releasing factor-containing neurons of the

32 eus of the hypothalamus and primarily in non-corticotropin releasing factor-containing neurons of the

33 gh an interaction between the stress hormone corticotropin releasing factor (CRF) and glutamate relea

34 The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (

35 The circadian activity of corticotropin releasing factor (CRF) and the hypothalami

36 The corticotropin releasing factor (CRF) antagonist, alpha-h

37 blocked by intravenous pretreatment with the corticotropin releasing factor (CRF) antagonist, astress

38 Corticotropin releasing factor (CRF) coordinates the bra

39 The corticotropin releasing factor (CRF) family of ligands a

40 The stress neuropeptide corticotropin releasing factor (CRF) is anxiogenic and i

41 Here we demonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neu

42 Corticotropin releasing factor (CRF) is the primary medi

43 of this study was to examine the ability of corticotropin releasing factor (CRF) or antibody to insu

44 Corticotropin releasing factor (CRF) plays a major role

45 port that the stress-associated neuropeptide corticotropin releasing factor (CRF) produces a profound

46 Reduced corticotropin releasing factor (CRF) receptor activity a

47 icotine withdrawal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expressi

48 Corticotropin releasing factor (CRF) regulates physiolog

49 Corticotropin releasing factor (CRF) signaling and CRF n

50 lar nucleus (PVN) have been shown to inhibit corticotropin releasing factor (CRF) synthesis via GABA(

51 The corticotropin releasing factor (CRF) system in the centr

52 The corticotropin releasing factor (CRF) system in the centr

53 The corticotropin releasing factor (CRF) type 1 receptor (CR

54 Corticotropin releasing factor (CRF) within the ventral

55 ontains a large number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide tha

56 intracerebroventricular (icv) injections of corticotropin releasing factor (CRF), a putative anxioge

57 analyzed brain regional, CCK-8, substance P, corticotropin releasing factor (CRF), and neuropeptide Y

58 for 15 days and measured mRNA expression of corticotropin releasing factor (CRF), neuropeptide Y (NP

59 until the corticotropes are stimulated with corticotropin releasing factor (CRF), whereupon SSTR2 ex

60 Urocortin 1 (Ucn 1) is an endogenous corticotropin releasing factor (CRF)-related peptide.

61 presence of the prototypical stress hormone, corticotropin releasing factor (CRF).

62 of action for the anxiogenic neuromodulator, corticotropin releasing factor (CRF).

63 ine seeking by the stress-sensitive peptide, corticotropin releasing factor (CRF).

64 The mammalian corticotropin releasing factor (CRF)/urocortin (Ucn) pep

65 Two new classes of tricyclic-based corticotropin-releasing factor (CRF(1)) receptor-1 antag

66 were measured at baseline and in response to corticotropin-releasing factor (CRF) (0.5 microg kg(1))

67 c raphe nucleus, including a coordination of corticotropin-releasing factor (CRF) actions at both of

68 We report that corticotropin-releasing factor (CRF) acts in the ventral

69 f chronic nicotine SA on the coexpression of corticotropin-releasing factor (CRF) and arginine vasopr

70 Although it has long been known that corticotropin-releasing factor (CRF) and CRF receptors a

71 ocus of the present review is on the role of corticotropin-releasing factor (CRF) and CRF-related pep

72 Long-term alterations in central corticotropin-releasing factor (CRF) and glucocorticoid

73 mRNA was found to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-

74 ajor site of extrahypothalamic expression of corticotropin-releasing factor (CRF) and its G-protein-c

75 Corticotropin-releasing factor (CRF) and nociceptin/orph

76 laced on the neuropharmacological actions of corticotropin-releasing factor (CRF) and norepinephrine

77 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the

78 Corticotropin-releasing factor (CRF) and related peptide

79 Corticotropin-releasing factor (CRF) and the closely rel

80 Corticotropin-releasing factor (CRF) and the three relat

81 Corticotropin-releasing factor (CRF) and urocortin (Ucn

82 Here we report the identification of corticotropin-releasing factor (CRF) as a critical compo

83 Exogenous corticotropin-releasing factor (CRF) but not corticoster

84 ng the endocrine arm of the stress response, corticotropin-releasing factor (CRF) can act in the brai

85 s-induced release of neuromodulators such as corticotropin-releasing factor (CRF) can drive drug-depe

86 To investigate corticotropin-releasing factor (CRF) contributions to fe

87 ses and how the stress-related neuropeptide, corticotropin-releasing factor (CRF) directs this by a b

88 neurons that release the stress neuropeptide corticotropin-releasing factor (CRF) drive anxiety-like

89 regulation of the central extrahypothalamic corticotropin-releasing factor (CRF) expression is assoc

90 -term effects of an acute colitis on central corticotropin-releasing factor (CRF) expression.

91 Urocortins are members of the corticotropin-releasing factor (CRF) family of peptides

92 The corticotropin-releasing factor (CRF) family of peptides

93 Urocortin 3 (Ucn 3), a member of the corticotropin-releasing factor (CRF) family of peptides,

94 Peptides of the corticotropin-releasing factor (CRF) family signal throu

95 Urocortin 2 (Ucn 2), a member of the corticotropin-releasing factor (CRF) family, and its cog

96 Urocortin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with

97 hypersecretion of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated

98 rofiling of relevant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a

99 ike ShA cocaine self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in th

100 gates the regulation of cytosolic calcium by corticotropin-releasing factor (CRF) in midbrain dopamin

101 ed body of work indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological

102 vioral studies support a modulatory role for corticotropin-releasing factor (CRF) in regulating the d

103 termined the role of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced b

104 was used to study immunoreactivity (IR) for corticotropin-releasing factor (CRF) in the guinea pig e

105 ed on previous work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during cr

106 lores the relationship between dynorphin and corticotropin-releasing factor (CRF) in the induction of

107 halin (ENK)] with the stress-related peptide corticotropin-releasing factor (CRF) in the LC.

108 bout the distribution of the stress hormone, corticotropin-releasing factor (CRF) in the mouse brain.

109 We recently described the existence of corticotropin-releasing factor (CRF) in the mouse cochle

110 ine was compared following overexpression of corticotropin-releasing factor (CRF) in the NAc of femal

111 dies have found that the stress neurohormone corticotropin-releasing factor (CRF) inhibits 5-HT neuro

112 literature suggests that catecholamines and corticotropin-releasing factor (CRF) interact in a seria

113 Stress induces the release of the peptide corticotropin-releasing factor (CRF) into the ventral te

114 Corticotropin-releasing factor (CRF) is a key mediator o

115 Corticotropin-releasing factor (CRF) is also known as a

116 Corticotropin-releasing factor (CRF) is an important lin

117 The neuropeptide corticotropin-releasing factor (CRF) is believed to play

118 Corticotropin-releasing factor (CRF) is critical for the

119 Corticotropin-releasing factor (CRF) is expressed in the

120 Corticotropin-releasing factor (CRF) mediates anxiogenic

121 The present experiments examined whether corticotropin-releasing factor (CRF) modulates memory co

122 rning of day 15, we measured AT(1) receptors corticotropin-releasing factor (CRF) mRNA and immunoreac

123 Corticotropin-releasing factor (CRF) mRNA expression in

124 rsal mPFC enhanced restraint-induced Fos and corticotropin-releasing factor (CRF) mRNA expression in

125 re to elicit reliable increases in Fos-ir or corticotropin-releasing factor (CRF) mRNA in the PVH.

126 ysis of Fos induction and relative levels of corticotropin-releasing factor (CRF) mRNA.

127 from chronic alcohol exposure contains ~80% corticotropin-releasing factor (CRF) neurons and that th

128 Although it has long-been known that corticotropin-releasing factor (CRF) neurons are promine

129 and anxiety and activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed

130 cohol intake specifically recruited GABA and corticotropin-releasing factor (CRF) neurons in the mPFC

131 Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should

132 the relationship between corticosterone and corticotropin-releasing factor (CRF) on both beta-amyloi

133 ed the effect of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabso

134 and the influence of the stress neuropeptide corticotropin-releasing factor (CRF) on these responses.

135 nced fear memory but did not increase either corticotropin-releasing factor (CRF) or corticosterone.

136 Injection of corticotropin-releasing factor (CRF) or urocortin III, k

137 Corticotropin-releasing factor (CRF) orchestrates the st

138 The corticotropin-releasing factor (CRF) peptide hormone fam

139 The corticotropin-releasing factor (CRF) plays a key role in

140 Because corticotropin-releasing factor (CRF) plays a role in str

141 Considerable evidence suggests that corticotropin-releasing factor (CRF) plays an important

142 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1)

143 duction and Abeta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signalin

144 Corticotropin-releasing factor (CRF) receptor activation

145 The corticotropin-releasing factor (CRF) receptor CRFR2 is e

146 Corticotropin-releasing factor (CRF) receptor subtypes 1

147 Corticotropin-releasing factor (CRF) receptors are found

148 Because corticotropin-releasing factor (CRF) receptors are impli

149 Corticotropin-releasing factor (CRF) receptors have been

150 We recently demonstrated that activation of corticotropin-releasing factor (CRF) receptors in the ca

151 ife social isolation increases the levels of corticotropin-releasing factor (CRF) receptors in the se

152 Corticotropin-releasing factor (CRF) receptors-which bin

153 The stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsa

154 induced relapse through alterations in brain corticotropin-releasing factor (CRF) regulation of neuro

155 Corticotropin-releasing factor (CRF) signaling at the CR

156 Alterations in corticotropin-releasing factor (CRF) signaling pathways

157 Activation of corticotropin-releasing factor (CRF) signaling pathways

158 Over the past few decades, corticotropin-releasing factor (CRF) signaling pathways

159 o negative reinforcement is a recruitment of corticotropin-releasing factor (CRF) signaling within th

160 Previous studies have implicated the brain corticotropin-releasing factor (CRF) stress systems in m

161 likely resulting from dysregulation of brain corticotropin-releasing factor (CRF) stress systems.

162 ment of the extrahypothalamic stress peptide corticotropin-releasing factor (CRF) system and activati

163 Dysregulation of the corticotropin-releasing factor (CRF) system has been imp

164 The corticotropin-releasing factor (CRF) system is the prima

165 eviously demonstrated that activation of the corticotropin-releasing factor (CRF) system potentiates

166 ess systems, including the extrahypothalamic corticotropin-releasing factor (CRF) system, following l

167 The corticotropin-releasing factor (CRF) system, which is in

168 f neonatal amygdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypotha

169 Corticotropin-releasing factor (CRF) that is released fr

170 The corticotropin-releasing factor (CRF) type 1 receptor (CR

171 Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (C

172 authors investigated the effect of blocking corticotropin-releasing factor (CRF) Type I and Type II

173 clase-activating peptide, PAC1 receptor, and corticotropin-releasing factor (CRF), (CRF1) receptor.

174 Corticotropin-releasing factor (CRF), a 41 amino acid pe

175 Here we report that corticotropin-releasing factor (CRF), a neuropeptide rel

176 The bimolecular interaction between corticotropin-releasing factor (CRF), a neuropeptide, an

177 nsistent with this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modul

178 he LC include excitatory amino acids (EAAs), corticotropin-releasing factor (CRF), and endogenous opi

179 (Dh44), a neuropeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor,

180 vitro and their modulation by dopamine (DA), corticotropin-releasing factor (CRF), and their combinat

181 The neuroactive substances corticotropin-releasing factor (CRF), arginine-vasopress

182 to the BNSTDL, is thought to communicate via corticotropin-releasing factor (CRF), but studies have y

183 The neuropeptide, corticotropin-releasing factor (CRF), coordinates the ph

184 Corticotropin-releasing factor (CRF), encoded by the CRH

185 -protein-coupled receptor B1 family includes corticotropin-releasing factor (CRF), growth hormone-rel

186 -adrenal (HPA) axis-activating neuropeptide, corticotropin-releasing factor (CRF), may be the keyston

187 ological studies indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dop

188 Corticotropin-releasing factor (CRF), originally charact

189 es in receptors for the stress neuropeptide, corticotropin-releasing factor (CRF), that render the lo

190 Corticotropin-releasing factor (CRF), the major stress p

191 The focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator o

192 Corticotropin-releasing factor (CRF), the stress-related

193 ways expressing the stress-sensitive peptide corticotropin-releasing factor (CRF), which has been ide

194 ral amygdala noradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism

195 allenge has been shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase i

196 Corticotropin-releasing factor (CRF)-mediated mechanisms

197 de transmitter in the brain that counteracts corticotropin-releasing factor (CRF)-mediated stress and

198 und that GluN2D is functionally expressed on corticotropin-releasing factor (CRF)-positive BNST cells

199 Corticotropin-releasing factor (CRF)-related peptides ca

200 Corticotropin-releasing factor (CRF)-related peptides mo

201 ) system by the stress-related neuropeptide, corticotropin-releasing factor (CRF).

202 agonists for the stress-related neurohormone corticotropin-releasing factor (CRF).

203 A major determinate of these responses is corticotropin-releasing factor (CRF).

204 n the lateral parabrachial nucleus coexpress corticotropin-releasing factor (CRF).

205 ntracerebroventricular infusion of saline or corticotropin-releasing factor (CRF).

206 action of the stress-associated neurohormone corticotropin-releasing factor (CRF).

207 nity monoclonal antibody, CTRND05, targeting corticotropin-releasing factor (CRF).

208 amygdala (CeA) that produce the neuropeptide corticotropin-releasing factor (CRF).

209 d reward, including neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).

210 vation of glucocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).

211 ation of VTA dopaminergic neurons expressing corticotropin-releasing factor (CRF).

212 known as maternal aggression) is impaired by corticotropin-releasing factor-(CRF) related peptides, b

213 ed neural cell density, stress neuropeptide (corticotropin releasing factor--CRF) levels, and plasma

214 This study tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK5616

215 ers of the corticoliberin family include the corticotropin releasing factors (CRFs), sauvagine, the u

216 -system recruitment of brain stress systems (corticotropin-releasing factor, dynorphin, norepinephrin

217 rom the basolateral amygdala (BLA) away from corticotropin releasing factor-expressing (CRF(+)) centr

218 rmones and is transcriptionally activated in corticotropin releasing factor-expressing cells.

219 ed with brain region-specific alterations of corticotropin-releasing factor expression and promoter m

220 The neuropeptides vasopressin and corticotropin-releasing factor facilitate, while seroton

221 oupled receptors, which bind peptides of the corticotropin releasing factor family and are key mediat

222 fashion both NGF and the hormone urotensin (corticotropin-releasing factor family ligand).

223 ortin 2, a recently identified member of the corticotropin-releasing factor family, is expressed in d

224 They further suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-ad

225 ephalin, thyrothropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in t

226 CRFR1) mediates the physiological actions of corticotropin-releasing factor in the anterior pituitary

227 tuitary-adrenal axis, including signaling by corticotropin-releasing factor, in the pathophysiology o

228 Corticotropin-releasing factor infusions into LA impair

229 Corticotropin-releasing factor infusions into the centra

230 in abnormal cerebrospinal fluid cortisol and corticotropin-releasing factor levels.

231 ated increments in restraint-induced Fos and corticotropin-releasing factor mRNA expression in the ne

232 w stress interacts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine

233 w explores the role of brain stress systems (corticotropin-releasing factor, norepinephrine, orexin [

234 s in the anterior hypothalamus that may gate corticotropin-releasing factor output from the amygdala

235 s an activation of the brain stress system's corticotropin-releasing factor outside of the hypothalam

236 were identified (i.e., serotonin, dynorphin, corticotropin-releasing factor, oxytocin).

237 in stress and appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B,

238 technique to a member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).

239 analysis showed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the

240 The current study examines the role of corticotropin releasing factor receptor subtypes 1 and 2

241 nvestigated here the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) a

242 tuted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) recep

243 methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) recep

244 cyclic imidazo[4,5-b]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF(1)) antagon

245 ss, the physiological consequence of central corticotropin-releasing factor receptor (CRF-R) activati

246 viously reported differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 i

247 c disruption of signaling through the type 1 corticotropin-releasing factor receptor (CRFR1).

248 Administration of the selective corticotropin-releasing factor receptor 1 (CRF(1)) antag

249 In addition, we examined the role of the corticotropin-releasing factor receptor 1 (CRF(1)) in th

250 We aimed to characterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antag

251 noradrenergic (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-depen

252 rial evaluating the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor

253 We describe a novel corticotropin-releasing factor receptor 1 (CRF1) antagon

254 Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppres

255 Corticotropin-releasing factor receptor 1 (CRFR1) mediat

256 Similarly to what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97

257 me proliferator-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable e

258 ecifically activated by either neurokinin I, corticotropin-releasing factor receptor 1, or dopamine D

259 Mice deficient in corticotropin-releasing factor receptor 2 (CRF2) (C57BL/

260 mutants with constitutive activation of the corticotropin-releasing factor receptor family homologue

261 anaphylaxis and psychological stress through corticotropin-releasing factor receptor subtype 1 (CRF(1

262 In this study we investigated the role of corticotropin-releasing factor receptor subtype 2 (CRF(2

263 d, we took the CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R)

264 esent study investigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1)

265 n reflect reductions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) po

266 we investigated interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) w

267 Corticotropin-releasing factor receptor type 1 (CRFR1) i

268 ular membrane compartments, we show that the corticotropin-releasing factor receptor type 1 has a spe

269 ure of the transmembrane domain of the human corticotropin-releasing factor receptor type 1 in comple

270 The corticotropin-releasing factor receptor type 1 is a clas

271 here this equilibrium is established for the corticotropin-releasing factor receptor type 1.

272 vation of the central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) h

273 Corticotropin-releasing factor receptor type 2 (CRFR2) h

274 eviously, we observed abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) t

275 The corticotropin-releasing factor receptor type 2a (CRF(2(a

276 Corticotropin-releasing factor receptor-1 (CRF(1)) media

277 n in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) anta

278 Effects on attention were attenuated by the corticotropin-releasing factor receptor-1 antagonist ant

279 NMR structure of the analogous domain of the corticotropin-releasing factor receptor.

280 Corticotropin-Releasing Factor Receptors (CRFRs) are cla

281 Corticotropin-releasing factor receptors (CRFRs), class

282 alysis studies it has been shown to increase corticotropin-releasing factor release in extrahypothala

283 Alterations in central corticotropin-releasing factor signaling pathways have b

284 ry-adrenal axis), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intes

285 In addition, corticotropin-releasing factor systems were shown to fac

286 is function was probed using a dexamethasone/corticotropin-releasing factor test.

287 ess effect by counteracting the functions of corticotropin-releasing factor, the primary stress-media

288 peptides (ghrelin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing ho

289 Corticotropin releasing factor type 1 (CRF1) is a key co

290 This hypothesis was investigated for the corticotropin-releasing factor type 1 (CRF(1)) receptor

291 hich oxytocin (OTR), vasopressin (V1aR), and corticotropin-releasing factor type 1 (CRF1) or type 2 r

292 Activation of corticotropin-releasing factor type 1 (CRF1) receptors i

293 icated that repeated social stress decreased corticotropin-releasing factor type 1 receptor and incre

294 We found that corticotropin-releasing factor type 1 receptor within th

295 disrupts this LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s)

296 disrupts this LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s)

297 re sensitive to central anorectic effects of corticotropin-releasing factor type 2 (CRF(2)) receptor

298 The corticotropin-releasing factor type 2 receptor (CRFR2) i

299 demonstrated that the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP ele

300 n the amygdala, which required activation of corticotropin-releasing factor type-1 (CRF-R1) receptors